SIBUTRAMINE REDUCES FOOD-INTAKE IN NON-DIETING WOMEN WITH OBESITY

Sibutramine (SIB), an inhibitor of serotonin and noradrenaline reuptak e, has been shown in clinical trials to be associated with a dose-rela ted decrease in bodyweight, This double-blind, placebo-controlled, Lat in square crossover study examined whether the effect on bodyweight co uld he due in part to a reduction in daily food intake, Twelve non-die ting, women with obesity (body mass index of 30.5 to 41.9) received th ree treatments (0 [matching placebo], 10, or 30 mg SIB/day) for 14 day s, with 14-day washout periods in between, On days 7 and 14, participa nts came to the laboratory to eat breakfast, lunch, and dinner so that daily energy and macronutrient intakes and ratings of hunger and sati ety could he measured, Significant reductions occurred in food intake (both grams and energy) over the 14-day study period, On day 7, SIB 30 reduced intake significantly by 1762 kJ (23% reduction from placebo), and on day 14, both SIB 10 and SIB 30 significantly reduced intake co mpared with placebo (SIB 10, 19% reduction [1490 kJ]; SIB 30, 26% redu ction [2079 kJ]). On day 7, the percentage of energy consumed from car bohydrate increased significantly with the 30-mg dose (56.7%) compared with that of placebo (51.3%), with a reciprocal decrease in energy fr om fat (27.8% to 24%). The results show that SIB reduced energy intake in women with obesity who were not attempting to lose weight.